	US 12,440,497 B2
	Compositions and methods for enhancing Wnt signaling for treating cancer
George Eng, Cambridge, MA (US); Omer Yilmaz, Cambridge, MA (US); and Jonathan Braverman, Cambridge, MA (US)
Assigned to MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, MA (US); and THE GENERAL HOSPITAL CORPORATION, Boston, MA (US)
Filed by Massachusetts Institute of Technology, Cambridge, MA (US); and The General Hospital Corporation, Boston, MA (US)
Filed on Oct. 7, 2022, as Appl. No. 18/045,059.
Claims priority of provisional application 63/253,380, filed on Oct. 7, 2021.
Prior Publication US 2023/0190767 A1, Jun. 22, 2023
Int. Cl. A61K 31/5517 (2006.01); A61K 31/497 (2006.01); A61K 31/5377 (2006.01); A61K 38/17 (2006.01); A61K 45/06 (2006.01); A61P 1/00 (2006.01); A61P 35/00 (2006.01); C07K 14/475 (2006.01)

CPC A61K 31/5517 (2013.01) [A61K 31/497 (2013.01); A61K 31/5377 (2013.01); A61K 38/1709 (2013.01); A61K 45/06 (2013.01); A61P 1/00 (2018.01); A61P 35/00 (2018.01); C07K 14/475 (2013.01)]

33 Claims

1. A method for treating cancer with overactivated Wnt in a subject in need thereof, comprising administering to the subject an effective amount of a composition comprising nanoparticles comprising a synthase kinase 3 (GSK-3) inhibitor for increasing Wnt signaling activity in the cancer cells,

wherein the GSK-3 inhibitor is selected from the group consisting of

C₂₈H₂₅FN₆O₃LY2090314,

C₁₉H₁₈FN₅O₂SAR502250, and

C₂₁H₂₃N₇O₃S AZD2858, and

a Wnt agonist to reduce cancer cell proliferation or viability in the subject.